Axonics, Inc. (AXNX) reported third-quarter 2021 net revenue of $46.9 million, reflecting a 33% increase from the prior year. Sacral neuromodulation (SNM) revenue reached $40.1 million, while Bulkamid generated $6.8 million. Despite the challenges posed by the Covid-19 Delta variant, the company noted significant demand for Bulkamid and positive feedback from 325 physicians trained in recent seminars. However, operating expenses rose to $47.7 million, resulting in a net loss of $17.3 million. Axonics adjusted its 2021 revenue guidance to $177 million, up 59% from 2020.
Axonics, Inc. (NASDAQ: AXNX) has been recognized as the fastest-growing publicly traded company in Orange County by the Orange County Business Journal. The company achieved a remarkable revenue increase from $3.3 million to $150.3 million over the past two years, showcasing a growth rate exceeding 4,500%. Axonics attributes its success to its mission-driven approach and innovation in incontinence solutions, currently employing over 550 staff. The company manufactures its products in Irvine, contributing positively to the local economy.
Axonics, Inc. (NASDAQ: AXNX) will release its third quarter 2021 financial results on November 4, 2021, after market close. Following the release, the company will conduct a conference call at 4:30 p.m. ET, accessible via phone and a live webcast. Axonics specializes in developing products for bladder and bowel dysfunction, including its rechargeable sacral neuromodulation system and Bulkamid® for urinary incontinence. The company serves a significant market with overactive bladder affecting an estimated 87 million adults in the U.S. and Europe.
Axonics, Inc. (NASDAQ: AXNX) has announced critical updates from the U.S. Patent Trial and Appeal Board (PTAB) regarding its contestation of three Medtronic patents. The PTAB's final decisions are an important step following Axonics' petitions filed in March 2020, which challenged the validity of the patents claimed to be infringed. Axonics views the decisions as favorable, particularly the invalidation of claims in Medtronic's '112 patent, which strengthens Axonics' non-infringement arguments. Axonics remains committed to its innovative solutions for bladder and bowel dysfunction.
Axonics (NASDAQ: AXNX) announced that the U.S. Patent Trial and Appeal Board (PTAB) issued final decisions on three of six patents from Medtronic that Axonics contests. The PTAB invalidated four claims of the '069 Patent while upholding claims of the '314 and '756 Patents, which will expire in 2022. Axonics plans to appeal the upheld claims but emphasizes that the decisions do not imply patent infringement. This outcome is viewed as a significant victory for Axonics, reflecting the strength of their arguments against Medtronic's claims.
Axonics, a medical technology company based in Irvine, California, announced its participation in three upcoming virtual investor conferences. The conferences include the Wells Fargo Healthcare Conference on September 9, 2021; the Morgan Stanley Healthcare Conference on September 13, 2021; and the Baird Healthcare Conference on September 15, 2021. The company specializes in developing products for bladder and bowel dysfunction, including a rechargeable sacral neuromodulation system and a urethral bulking agent. A webcast of the presentations will be available on their investor relations website.
Axonics, Inc. (NASDAQ: AXNX) reported a record revenue of $45.9 million for Q2 2021, up 202% from $15.2 million a year ago. Sacral neuromodulation revenue reached $40.2 million, with a gross margin of 62.6%. The company raised its 2021 revenue guidance to $186-$188 million, reflecting a 67%-69% increase over 2020. Despite a net loss of $25.1 million, cash reserves stood at $231.1 million after terminating a $75 million loan. Recent milestones include FDA approval for a non-rechargeable implant and significant training initiatives for its Bulkamid product.
Axonics, Inc. (Nasdaq: AXNX) has appointed Esteban López, M.D., MBA, to its board of directors. Dr. López brings significant healthcare experience, currently serving as the Americas healthcare and life sciences Market Lead at Google Cloud and previously as chief medical officer at Health Care Service Corporation. With a strong background in innovation and strategy, he is expected to play a crucial advisory role as Axonics pursues its growth objectives in treating bladder and bowel dysfunction. His clinical expertise enhances the board's capabilities in addressing patient needs.
BioLife Solutions (Nasdaq: BLFS) has announced changes to its board of directors, effective July 12, 2021. Raymond W. Cohen resigned from the board after serving since 2006 and as chairman since 2013. Mike Rice, the current CEO, has been appointed as the new chairman. Cohen expressed gratitude for his time at BioLife, highlighting the company's growth in bioproduction tools for cell and gene therapies. The leadership transition aims to ensure continued strategic direction and growth.
Axonics, Inc. (Nasdaq: AXNX) is set to release its second quarter 2021 financial results on August 5, 2021, after market close. The company will host a conference call at 4:30 p.m. Eastern Time, accessible via phone or a live webcast on its investor relations website. Axonics specializes in medical technology for bladder and bowel dysfunction, offering innovative products like its rechargeable sacral neuromodulation system and Bulkamid®, a urethral bulking agent. These products address overactive bladder, fecal incontinence, and stress urinary incontinence, with established reimbursement coverage in the U.S. and Europe.